Viewing data from:

PROCHLORPERAZINE MALEATE

ANDA

PROCHLORPERAZINE MALEATE | A216595 | GLENMARK PHARMACEUTICALS LTD

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 2 NDCs

Highest NADAC/Unit

$0.1741

per ea

Lowest NADAC/Unit

$0.1155

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
68462094701PROCHLORPERAZINE 10 MG TAB	$0.1741	EA	Generic	—	2026-06-17
68462088901PROCHLORPERAZINE 5 MG TABLET	$0.1155	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (2 FSS)

Lowest Price

$21.60

Highest Price

$32.45

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
68462-0889-01PROCHLORPERAZINE MALEATE 5MG TAB	$21.60	FSS	GLENMARK PHARMACEUTICALS INC., USA	10/14/2027
68462-0947-01PROCHLORPERAZINE MALEATE 10MG TAB	$32.45	FSS	GLENMARK PHARMACEUTICALS INC., USA	10/14/2027

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain3 active DMFs4 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

TRIFARMA SPAPROCHLORPERAZINE MALEATE

DMF 23681974

BIOPHORE INDIA PHARMACEUTICALS PVT LTDPROCHLORPERAZINE MALEATE

DMF 318422017

RAKS PHARMA PVT LTDPROCHLORPERAZINE MALEATE USP

DMF 361732021

INDUSTRIA CHIMICA MILANESE SPAInactivePROCHLORPERAZINE MALEATE

DMF 4681962

PHENCHEM INDUSTRIES LTDInactivePROCHLORPERAZINE MALEATE

DMF 25931976

CYCLO PRODUCTS INCInactivePROCHLORPERAZINE MALEATE U.S.P.

DMF 30781977

EGIS PHARMACEUTICALS PRIVATE LTDInactivePROCHLORPERAZINE MALEATE

DMF 93641991

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 5MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Mar 17, 2023

No patent or exclusivity listings for this strength.

#002 — EQ 10MG BASE

0 patents0 exclusivities▾

TABLET;ORAL | Approved: Mar 17, 2023